A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors
暂无分享,去创建一个
Didier Rognan | Esther Kellenberger | Jordi Rodrigo | E. Kellenberger | D. Rognan | Jean-Sébastien Surgand | J. Rodrigo | Jean‐Sebastien Surgand
[1] Didier Rognan,et al. Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.
[2] F. Monsma,et al. Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. , 2002, Molecular pharmacology.
[3] C. Maggi,et al. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor. , 1999, The Journal of pharmacology and experimental therapeutics.
[4] International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome , 2001, Nature.
[5] Jussi Taipale,et al. Small molecule modulation of Smoothened activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Krogh,et al. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. , 2001, Journal of molecular biology.
[7] L. F. Kolakowski. GCRDb: a G-protein-coupled receptor database. , 1994, Receptors & channels.
[8] R. DeVita,et al. Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[9] Kolakowski Lf. GCRDB: A G-PROTEIN-COUPLED RECEPTOR DATABASE , 1994 .
[10] R. Jensen,et al. Identification of Four Amino Acids in the Gastrin-releasing Peptide Receptor That Are Required for High Affinity Agonist Binding* , 1997, The Journal of Biological Chemistry.
[11] C. Strader,et al. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. , 1994, Biochemistry.
[12] T. Bártfai,et al. Modes of Peptide Binding in G Protein-Coupled Receptors , 1997, Neurochemical Research.
[13] S. O. Smith,et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[14] T. Bártfai,et al. Mutagenesis and ligand modification studies on galanin binding to its GTP-binding-protein-coupled receptor GalR1. , 1997, European journal of biochemistry.
[15] R. Leurs,et al. Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.
[16] J. Findlay,et al. Interaction of Met297 in the seventh transmembrane segment of the tachykinin NK2 receptor with neurokinin A. , 2001, The Journal of biological chemistry.
[17] P. Kitabgi,et al. Mutagenesis and Modeling of the Neurotensin Receptor NTR1 , 1998, The Journal of Biological Chemistry.
[18] S. Rivkees,et al. Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.
[19] Beth A. Fleck,et al. Phenylguanidines as selective nonpeptide melanocortin-5 receptor antagonists. , 2004, Journal of medicinal chemistry.
[20] N. Illing,et al. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions. , 1997, Reviews of reproduction.
[21] R. Jensen,et al. Two amino acids in the sixth transmembrane segment of the mouse gastrin-releasing peptide receptor are important for receptor activation. , 2000, The Journal of pharmacology and experimental therapeutics.
[22] R. Kühne,et al. Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. , 2000, Molecular endocrinology.
[23] Matthias Keil,et al. Identifification of Substrate Channels and Protein Cavities , 1998 .
[24] David E. Gloriam,et al. Seven evolutionarily conserved human rhodopsin G protein‐coupled receptors lacking close relatives , 2003, FEBS letters.
[25] Binding crevice for TT-232 in a homology model of type 1 somatostatin receptor. , 2004, Biochemical and biophysical research communications.
[26] J. Regan,et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. , 1994, Molecular pharmacology.
[27] Roy G. Smith,et al. Cloning and characterization of two human G protein-coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. , 1997, Genomics.
[28] W. Boyar,et al. Residues 21–30 within the Extracellular N-terminal Region of the C5a Receptor Represent a Binding Domain for the C5a Anaphylatoxin* , 1998, The Journal of Biological Chemistry.
[29] J. Wang,et al. Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors , 2000, Inflammation Research.
[30] J. Tsukada,et al. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor. , 2002, Journal of medicinal chemistry.
[31] J. Barrish,et al. Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity. , 1996, Biochemistry.
[32] Takao Shimizu,et al. Identification of p2y9/GPR23 as a Novel G Protein-coupled Receptor for Lysophosphatidic Acid, Structurally Distant from the Edg Family* , 2003, Journal of Biological Chemistry.
[33] R. Maki,et al. Molecular Determinants of Melanocortin 4 Receptor Ligand Binding and MC4/MC3 Receptor Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.
[34] B. Kobilka. Agonist binding: a multistep process. , 2004, Molecular pharmacology.
[35] G. Tigyi. Selective ligands for lysophosphatidic acid receptor subtypes: gaining control over the endothelial differentiation gene family. , 2001, Molecular pharmacology.
[36] Alan Wise,et al. The identification of ligands at orphan G-protein coupled receptors. , 2004, Annual review of pharmacology and toxicology.
[37] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] J. Ballesteros,et al. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. , 2002, The Journal of biological chemistry.
[39] J S Mills,et al. Characterization of the Binding Site on the Formyl Peptide Receptor Using Three Receptor Mutants and Analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu* , 2000, The Journal of Biological Chemistry.
[40] A. Tartar,et al. Non-peptide oxytocin agonists. , 2004, Bioorganic & medicinal chemistry letters.
[41] P. Lockey,et al. New non peptidic C5a receptor antagonists , 1997 .
[42] R. Martinez,et al. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. , 1996, Molecular pharmacology.
[43] J. Tsukada,et al. Synthesis and Pharmacological Evaluation of 5-(4-Biphenyl)-3-methyl-4-phenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human Vasopressin V1A Receptor , 2002 .
[44] S. Urwyler,et al. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and Structurally Related Compounds: Novel Allosteric Enhancers of γ-Aminobutyric AcidB Receptor Function , 2003, Journal of Pharmacology and Experimental Therapeutics.
[45] N. Cotte,et al. Docking of linear peptide antagonists into the human V(1a) vasopressin receptor. Identification of binding domains by photoaffinity labeling. , 1999, The Journal of biological chemistry.
[46] Natesan Murugesan,et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. , 2002, Journal of medicinal chemistry.
[47] T. Shinohara,et al. Identification of a G Protein-coupled Receptor Specifically Responsive to β-Alanine* , 2004, Journal of Biological Chemistry.
[48] T. Lundstedt,et al. Classification of G‐protein coupled receptors by alignment‐independent extraction of principal chemical properties of primary amino acid sequences , 2002, Protein science : a publication of the Protein Society.
[49] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[50] Jyoti R. Patel,et al. Biaryl amide glucagon receptor antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[51] A. Kopin,et al. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides. , 2000, Molecular pharmacology.
[52] O. Vakkuri,et al. Important amino acids for the function of the human MT1 melatonin receptor. , 2003, Biochemical pharmacology.
[53] Hugo Kubinyi,et al. Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective , 2004 .
[54] P Ferrara,et al. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.
[55] K. Jacobson,et al. A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. , 1997, Molecular pharmacology.
[56] Didier Rognan,et al. High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening , 2004, J. Chem. Inf. Model..
[57] B. Dominy,et al. trans-3-Benzyl-4-hydroxy-7-chromanylbenzoic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor. , 1998, Bioorganic & medicinal chemistry letters.
[58] T. Elworthy. Lactams as EP4 Prostanoid Receptor Subtype Selective Agonists. Part 1. 2-Pyrrolidinones — Stereochemical and Lower Side-Chain Optimization. , 2004 .
[59] Didier Rognan,et al. Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors* , 2003, Journal of Biological Chemistry.
[60] M. Dubocovich,et al. Mutagenesis studies of the human MT2 melatonin receptor. , 2003, Biochemical pharmacology.
[61] David J. Anderson,et al. Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Gαq/11 pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[62] M. Maccoss,et al. Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. , 2003, Biochemistry.
[63] I. Gantz,et al. Molecular Basis for the Interaction of [Nle4,d-Phe7]Melanocyte Stimulating Hormone with the Human Melanocortin-1 Receptor (Melanocyte α-MSH Receptor)* , 1997, The Journal of Biological Chemistry.
[64] K. Jacobson,et al. Identification by Site-directed Mutagenesis of Residues Involved in Ligand Recognition and Activation of the Human A3 Adenosine Receptor* , 2002, The Journal of Biological Chemistry.
[65] Thomas J. Hudson,et al. Characterization of a Common Susceptibility Locus for Asthma-Related Traits , 2004, Science.
[66] Susumu Goto,et al. LIGAND: database of chemical compounds and reactions in biological pathways , 2002, Nucleic Acids Res..
[67] H. Iwaasa,et al. Different binding sites for the neuropeptide Y Y1 antagonists 1229U91 and J-104870 on human Y1 receptors , 2001, Peptides.
[68] M. Billah,et al. The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103,392 differ. , 1999, Bioorganic & medicinal chemistry.
[69] M. Gouy,et al. WWW-query: an on-line retrieval system for biological sequence banks. , 1996, Biochimie.
[70] K. Jacobson,et al. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. , 2004, Journal of medicinal chemistry.
[71] C. E. Peishoff,et al. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity: evidence for the overlap of peptide and non-peptide ligand binding sites. , 1994, Biochemistry.
[72] J. Kemp,et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[73] R. Osman,et al. A hydrophobic cluster between transmembrane helices 5 and 6 constrains the thyrotropin-releasing hormone receptor in an inactive conformation. , 1998, Molecular pharmacology.
[74] M. Maccoss,et al. Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor* , 1999, The Journal of Biological Chemistry.
[75] S. Narumiya,et al. Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.
[76] R. Jensen,et al. An aspartate residue at the extracellular boundary of TMII and an arginine residue in TMVII of the gastrin-releasing peptide receptor interact to facilitate heterotrimeric G protein coupling. , 1999, Biochemistry.
[77] R. Jensen,et al. Molecular Basis for Selectivity of High Affinity Peptide Antagonists for the Gastrin-releasing Peptide Receptor* , 2001, The Journal of Biological Chemistry.
[78] J. Ballesteros,et al. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.
[79] John Hwa,et al. The Unique Ligand-binding Pocket for the Human Prostacyclin Receptor , 2003, The Journal of Biological Chemistry.
[80] J. Bockaert,et al. A 5-HT4 Receptor Transmembrane Network Implicated in the Activity of Inverse Agonists but Not Agonists* , 2002, The Journal of Biological Chemistry.
[81] P. Monk,et al. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor. , 2001, Biochemistry.
[82] A. IJzerman,et al. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[83] S. Moro,et al. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. , 1998, Journal of medicinal chemistry.
[84] L. Pardo,et al. A molecular dissection of the glycoprotein hormone receptors. , 2004, Trends in biochemical sciences.
[85] A. IJzerman,et al. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. , 1996, Molecular pharmacology.
[86] P. Murphy,et al. The Endogenous Opioid Spinorphin Blocks fMet-Leu-Phe-Induced Neutrophil Chemotaxis by Acting as a Specific Antagonist at the N-Formylpeptide Receptor Subtype FPR , 2001, The Journal of Immunology.
[87] M. Tota,et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. , 2000, Biochemistry.
[88] J. Ballesteros,et al. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.
[89] David E. Gloriam,et al. The human and mouse repertoire of the adhesion family of G-protein-coupled receptors. , 2004, Genomics.
[90] Evi Kostenis,et al. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. , 2005, Bioorganic & medicinal chemistry letters.
[91] D. Rognan,et al. Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.
[92] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[93] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[94] L. M. Leeb-Lundberg,et al. A Single Position in the Third Transmembrane Domains of the Human B1 and B2 Bradykinin Receptors Is Adjacent to and Discriminates between the C-terminal Residues of Subtype-selective Ligands* , 1998, The Journal of Biological Chemistry.
[95] S. Gordon,et al. The EGF-TM7 family: a postgenomic view , 2003, Immunogenetics.
[96] Gilles Labesse,et al. No Ligand Binding in the GB2 Subunit of the GABABReceptor Is Required for Activation and Allosteric Interaction between the Subunits , 2002, The Journal of Neuroscience.
[97] M. Fidock,et al. MrgX2 Is a High Potency Cortistatin Receptor Expressed in Dorsal Root Ganglion* , 2003, Journal of Biological Chemistry.
[98] Yue Zhang,et al. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan. , 1994, The Journal of biological chemistry.
[99] J. Wess,et al. Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. , 1995, Life sciences.
[100] Konstantin V. Balakin,et al. Property-Based Design of GPCR-Targeted Library , 2002, J. Chem. Inf. Comput. Sci..
[101] F. Monsma,et al. Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. , 1998, Molecular pharmacology.
[102] R. Kühne,et al. Impact of aromatic residues within transmembrane helix 6 of the human gonadotropin-releasing hormone receptor upon agonist and antagonist binding. , 2002, Biochemistry.
[103] Anthony J Harmar,et al. Family-B G-protein-coupled receptors , 2001, Genome Biology.
[104] J. Ballesteros,et al. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.
[105] Toshihiko Okada,et al. Synthesis and biological activity of various derivatives of a novel class of potent, selective, and orally active prostaglandin D2 receptor antagonists. 1. Bicyclo[2.2.1]heptane derivatives. , 2003, Journal of medicinal chemistry.
[106] S. Hoare,et al. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. , 2005, Drug discovery today.
[107] Roger Crossley. The design of screening libraries targeted at G-protein coupled receptors. , 2004, Current topics in medicinal chemistry.
[108] Francine Acher,et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[109] C. Maggi,et al. Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis , 2000, Neuropharmacology.
[110] S. Pong,et al. A nonpeptidyl growth hormone secretagogue. , 1993, Science.
[111] David J. Anderson,et al. A Diverse Family of GPCRs Expressed in Specific Subsets of Nociceptive Sensory Neurons , 2001, Cell.
[112] Jinhai Gao,et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors , 2004, Nature.
[113] Fujun Li,et al. Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization. , 2004, Bioorganic & medicinal chemistry letters.
[114] U. Gether. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.
[115] L. Prézeau,et al. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. , 2003, Pharmacology & therapeutics.
[116] A. Parrill,et al. A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors* , 2001, The Journal of Biological Chemistry.
[117] Brigitte L. Kieffer,et al. Role of Aromatic Transmembrane Residues of the -Opioid Receptor in Ligand Recognition (*) , 1996, The Journal of Biological Chemistry.
[118] B. Maigret,et al. Control of Conformational Equilibria in the Human B2 Bradykinin Receptor , 2001, The Journal of Biological Chemistry.
[119] R. Osman,et al. Distinct roles for arginines in transmembrane helices 6 and 7 of the thyrotropin-releasing hormone receptor. , 1995, Molecular pharmacology.
[120] R. Osman,et al. Hydrogen bonding interaction of thyrotropin-releasing hormone (TRH) with transmembrane tyrosine 106 of the TRH receptor. , 1994, The Journal of biological chemistry.
[121] Gert Vriend,et al. GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..
[122] T K Attwood,et al. Fingerprinting G-protein-coupled receptors. , 1994, Protein engineering.
[123] F. Raulf,et al. Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201‐995 for the SSTR2 somatostatin receptor. , 1995, The EMBO journal.
[124] Trond Ulven,et al. 4-Acylamino-and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. , 2004, Bioorganic & medicinal chemistry letters.
[125] B. Roth,et al. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. , 1998, Pharmacology & therapeutics.
[126] J Hoflack,et al. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.
[127] F Guarnieri,et al. A refined model of the thyrotropin-releasing hormone (TRH) receptor binding pocket. Experimental analysis and energy minimization of the complex between TRH and TRH receptor. , 1996, Biochemistry.
[128] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[129] C Evans,et al. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. , 1996, Molecular pharmacology.
[130] Robert P Bywater,et al. Location and nature of the residues important for ligand recognition in G‐protein coupled receptors , 2005, Journal of molecular recognition : JMR.
[131] A. Gubitz,et al. Chimeric and point-mutated receptors reveal that a single glycine residue in transmembrane domain 6 is critical for high affinity melatonin binding. , 2000, Endocrinology.
[132] P. Morgan,et al. Chimeric Melatonin mt1 and Melatonin-related Receptors , 2000, The Journal of Biological Chemistry.
[133] D. E. Clark,et al. A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.
[134] C. Broger,et al. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. , 1995, European journal of biochemistry.
[135] D. Banville,et al. Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs , 2002, Nature Neuroscience.
[136] Frank Diehl,et al. Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists , 2000, The Journal of Biological Chemistry.
[137] E. De Clercq,et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. , 2001, Molecular pharmacology.
[138] T. Langer,et al. Chemical function based pharmacophore generation of endothelin-A selective receptor antagonists. , 2004, Journal of medicinal chemistry.
[139] Thomas Walther,et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[140] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[141] A. IJzerman,et al. Lys 199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists , 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[142] J. Schanstra,et al. [Bradykinin receptors: towards new pathophysiological roles]. , 2003, Medecine sciences : M/S.
[143] P. Plas,et al. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. , 2001, Journal of medicinal chemistry.
[144] T. Saito,et al. An evolutionarily conserved G-protein coupled receptor family, SREB, expressed in the central nervous system. , 2000, Biochemical and biophysical research communications.
[145] T. Guo,et al. Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. , 2003, Assay and drug development technologies.
[146] D. Donnelly,et al. The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor. , 1996, The Journal of Biological Chemistry.
[147] W. Greenlee,et al. A nonpeptidic agonist ligand of the human C5a receptor: Synthesis, binding affinity optimization and functional characterization , 1997 .
[148] H. Wichterle,et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[149] David H. Coy,et al. Tyrosine 220 in the 5th Transmembrane Domain of the Neuromedin B Receptor Is Critical for the High Selectivity of the Peptoid Antagonist PD168368* , 2001, The Journal of Biological Chemistry.
[150] H. Akil,et al. Hydrophobic Residues of the D2 Dopamine Receptor Are Important for Binding and Signal Transduction , 1995, Journal of neurochemistry.
[151] J Hoflack,et al. Functional architecture of vasopressin/oxytocin receptors. , 1999, Journal of receptor and signal transduction research.
[152] Yi-Jun Guo,et al. Molecular basis for the interaction of histamine with the histamine H2 receptor. , 1992, The Journal of biological chemistry.
[153] K. Chou,et al. A study on the correlation of G-protein-coupled receptor types with amino acid composition. , 2002, Protein engineering.
[154] Elaine C. Meng,et al. An Activation Switch in the Ligand Binding Pocket of the C5a Receptor* , 2001, The Journal of Biological Chemistry.
[155] J. Bascands,et al. Les récepteurs de la bradykinine: de nouveaux rôles physio- pathologiques , 2003 .
[156] Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. , 1997, Molecular endocrinology.
[157] R G Smith,et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. , 1998, Science.
[158] S. Dowell,et al. Mutagenesis of human Mel1a melatonin receptor expressed in yeast reveals domains important for receptor function. , 1998, Biochemical and biophysical research communications.
[159] Robert P Bywater,et al. Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.
[160] W. S. Faraci,et al. CP-99,711: a non-peptide glucagon receptor antagonist , 1992 .
[161] P. Sneath,et al. Numerical Taxonomy , 1962, Nature.
[162] A. Dalpiaz,et al. C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor. , 2002, European journal of pharmacology.
[163] H. Toh,et al. Molecular evolution of receptors for eicosanoids , 1995, FEBS letters.
[164] N. Nirmala,et al. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. , 2003, Molecular pharmacology.
[165] C. Strader,et al. Genetic approaches to the determination of structure-function relationships of G protein-coupled receptors. , 1989, Trends in pharmacological sciences.
[166] P. Ferrara,et al. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding. , 1999, European journal of pharmacology.
[167] Kurt Kristiansen,et al. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.
[168] R. Adan,et al. AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor. , 2001, Molecular endocrinology.
[169] P. Morgan,et al. The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor. , 1997, Biochemical and biophysical research communications.
[170] R. Neubig,et al. Depicting a protein's two faces: GPCR classification by phylogenetic tree‐based HMMs , 2003, FEBS letters.
[171] D. Underwood,et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. , 1998, Molecular endocrinology.
[172] S. Tunaru,et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.
[173] C. Derian,et al. Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide. , 2001, Bioorganic & medicinal chemistry letters.
[174] H. Niznik,et al. The somatostatin receptor family. , 1995, Life sciences.
[175] E. Jacoby. A Novel Chemogenomics Knowledge-Based Ligand Design Strategy—Application to G Protein-Coupled Receptors , 2001 .
[176] B. Maigret,et al. The Biologically Crucial C Terminus of Cholecystokinin and the Non-peptide Agonist SR-146,131 Share a Common Binding Site in the Human CCK1 Receptor , 2002, The Journal of Biological Chemistry.
[177] T. Ulven,et al. 4‐Acylamino‐ and 4‐Ureidobenzamides as Melanin‐Concentrating Hormone (MCH) Receptor 1 Antagonists , 2005 .
[178] D. Underwood,et al. Arginine 206 of the C5a Receptor Is Critical for Ligand Recognition and Receptor Activation by C-terminal Hexapeptide Analogs (*) , 1995, The Journal of Biological Chemistry.
[179] M. Peitsch,et al. Role of a hydrophobic pocket of the human Y1 neuropeptide Y receptor in ligand binding , 1995, Molecular and Cellular Endocrinology.
[180] T K Attwood,et al. A compendium of specific motifs for diagnosing GPCR subtypes. , 2001, Trends in pharmacological sciences.
[181] M. Jiang,et al. A human opsin-related gene that encodes a retinaldehyde-binding protein. , 1994, Biochemistry.
[182] J. Ballesteros,et al. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.
[183] S. Urwyler,et al. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. , 2001, Molecular pharmacology.
[184] H. Schiöth,et al. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.
[185] Modest von Korff,et al. GPCR-Tailored Pharmacophore Pattern Recognition of Small Molecular Ligands , 2004, J. Chem. Inf. Model..
[186] J. Loureiro,et al. The Wnts , 1999, Current Biology.
[187] J. Murphy,et al. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. , 1999, The Journal of pharmacology and experimental therapeutics.
[188] J. Ballesteros,et al. Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.
[189] A. Methner,et al. Phylogenetic analysis of 277 human G-protein-coupled receptors as a tool for the prediction of orphan receptor ligands , 2002, Genome Biology.
[190] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[191] P. Prusis,et al. Characterisation of D117A and H260A mutations in the melanocortin 1 receptor , 1997, Molecular and Cellular Endocrinology.
[192] Evi Kostenis,et al. Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. , 2002, Cellular signalling.
[193] S. Narumiya,et al. Identification of Domains Conferring Ligand Binding Specificity to the Prostanoid Receptor , 1997, The Journal of Biological Chemistry.
[194] C. Strader,et al. Molecular characterization of the melanin-concentrating hormone/receptor complex: identification of critical residues involved in binding and activation. , 2000, Molecular pharmacology.
[195] I. Okun,et al. Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as selective endothelin receptor-A antagonists. , 1997, Journal of medicinal chemistry.
[196] M. Jurzak,et al. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[197] David Haussler,et al. Classifying G-protein coupled receptors with support vector machines , 2002, Bioinform..
[198] C. S. Gal,et al. Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor. , 2004, Molecular endocrinology.